Can we justify the continued use of botulinum toxin A in the management of myofascial pain? by Haworth, Simon et al.
                          Haworth, S., Farrier, J. N., Haworth, S., & Beech, A. (2020). Can we
justify the continued use of botulinum toxin A in the management of





Link to published version (if available):
10.1016/j.bjoms.2020.06.024
Link to publication record in Explore Bristol Research
PDF-document
This is the author accepted manuscript (AAM). The final published version (version of record) is available online
via Elsevier at https://doi.org/10.1016/j.bjoms.2020.06.024. Please refer to any applicable terms of use of the
publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the
published version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/




We initially performed a pilot study to evaluate the impact of botulinum toxin A (BtA) on increased 
masseteric mass with associated pain. We assessed the impact on the muscle mass and the 
impact, if any, on each patient’s reported pain before and after injection in a group of 10 patients 
who were refractory to conservative management methods. Results of this pilot study indicated 
that clenched and unclenched muscle dimensions showed no statistically significant reduction (-
0.82 clenched and -1mm unclenched). However, what did prove to be significant was an 
improvement in their pain scores as measured on a Visual Analogue Scale (VAS). Pre-injection 
mean VAS score was 8.2 and 1.8 at 6 weeks post-injection. Following the pilot study we focused 
just on patients’ pain scores. Our main study included 48 patients (81 muscles) who suffered with 
pain secondary to increased masseteric size whom indicated their pain score out of 10 on the VAS 
prior to placement of BtA in to each affected masseter muscle, and a further pain-score recording 
6 weeks post-injection. Results showed a mean pre-injection pain score of 7.9 and a mean post-
injection pain score of 2.9. Our trust has allowed funding to provide the intramuscular injection of 
BtA in appropriately selected patients following  the results of this study on reported pain alone, 












Masseteric hypertrophy is a condition that presents as a unilateral or bilateral swelling in the 
region of the angle of the mandible (1). Increased muscle mass can also be caused by myospasm 
linked to myofascial pain and dysfunction (MPD) or in fact a combination of the two (2). The 
aetiology is unclear but might include increased work muscle mass due to parafunctional habits 
e.g. chewing gum, bruxism or changes in proprioceptive influences (3,4). This increase in muscle 
volume has been linked to temporomandibular joint disorder, focal dystonia and the premature 
loss of teeth (3, 4).  
 
Diagnosis is achieved by simple clinical examination but investigations such as plain view 
radiography, computed tomography, magnetic resonance scanning and ultrasound scanning 
(1,3,4,5) can be helpful. Muscle biopsy has also been described (1) and this or direct surgical view 
of the affected muscle is usually the only way of definitively diagnosing between hypertrophy and 
myospasm. Patients can complain of the cosmetic appearance of the enlargement of the masseter 
muscle (3) which can be accompanied by trismus and pain (3,6,7) impacting on daily activities e.g. 
eating and talking. 
 
Treatment of increased masseteric mass with associated pain and functional impairment can 
involve the excision of part of the masseter muscle by an intra-oral and/or an extra-oral approach 
(1-4) or removal of part of the mandibular ramus (6,7). These options are invasive and can lead to 
significant post-operative morbidity. A less invasive option includes the injection of botulinum 
toxin A (BtA) in to the masseter muscle (1-7). We have been using the technique for several years 
in our unit, although little evidence on its reduction in pain, impact on quality of life (QoL) or 
muscle mass is present in the available literature. 
 
The cost of BtA is not insignificant and with the growing importance of patient reported outcome 
measures in the provision of healthcare, within the current financial climate, it is important to 
ascertain that a treatment modality is effective and how just how much information is needed to 
support this. 
 
Our aim was to determine whether patients find BtA beneficial in the management of increase in 
masseteric mass with accompanying pain. In a pilot study we performed pre- and post- injection 
ultrasonography and recorded any impact on muscle mass plus reported pain scores in the same 
group of patients, and then continued on to a further study of simply looking at myofascial pain 




Patients and Methods 
 
Pilot study 
A pilot study included 10 patients, all of which had a degree of unilateral or bilateral masseteric 
hypertrophy/ enlargement and complained of pain plus patient perceived difficulty in mouth 
opening. 3 patients had unilateral pain and 7 had bilateral pain.  
 
Patients included in the study had previously undertaken a 3 month period of jaw exercises 
following assessment by a specialist physiotherapist in the hospital. They had also been advised on 
daily warm compresses, massage and taking regular analgesia/ non-steroidal anti-inflammatory 
medication during this time period. Parafunctional habits were identified and excluded. If any 
bruxists were identified a lower soft acrylic 2mm mouthguard was prescribed by their dentists and 
worn nightly. At 3-month review, if the patient reported little or no improvement in pain and they 
remained to have clear masseteric enlargement on clinical examination, they were then recruited 
in to the study. Hypertrophy and pain reporting was not measured prior to 3 months of 
conservative management. No exclusions were made over age or gender, all patients were classed 
as grade I or II by the American Society of Anaesthesiologists’ physical classification system. No 
patients were rejected after the study began.  
 
Suitable patients were recruited consecutively after assessment by the same Consultant Oral and 
Maxillofacial Surgeon. Directly prior to recruitment they had temporomandibular joint open and 
closed mouth plain radiographs to assess movement and formation of the mandibular condyle to 
exclude pathology. If they did they were excluded from the study and further imaging and 
appropriate treatment offered. Exclusion was also made if they had previously had the injection of 
BtA in to their masseter muscle/s or any previous temporomandibular joint surgery. No patients 
recruited had an MRI scan. No patients were rejected after the start of the pilot study. 
 
Prior to intervention with BtA measurements were taken of affected masseter muscles using 
ultrasonography. The machine used was LOGIC™ P9 (GE Healthcare). Measurements were taken 
with each patient at rest and also whilst clenching at the maximum distance form superficial to 
deep aspects of the masseter at 90 degrees to the skin surface. Each patient had ultrasound 
scanning by the same Consultant radiologist within 4 weeks prior to, and at 6 weeks post, injection 
of BtA. Measurements were taken at the maximum thickness of the muscle.  
 
All patients were administered the intra-muscular injection of BtA by the same consultant oral and 
maxillofacial surgeon. The drug used for injection was Allergan (Allergan Limited, The Parkway, 
Marlow, England). Each 50unit vial of Allergan (Botox ®) was diluted with normal saline to a 
concentration of 25 units/mL. Each muscle received the injection of 25 units/mL. At administration 
the muscle was palpated and BtA injected in to the thickest, or most hypertrophied, part of the 
muscle. Injection was with a fine 25-gauge needle after aspiration to avoid intravenous placement.  
 
Patients were asked to record their pain associated with their masseter muscles on a visual 
analogue scale (VAS) (Figure 1) on a scale of 1-10, with 10 being the worst pain imaginable, just 
before the administration of BtA and also 6 weeks later at review on the same day as their post-
injection ultrasound scan. These were retained in the patient’s hospital notes.  
 
Pre- and post-treatment VAS scores were compared using a paired T test. Pre- and post- treatment 
muscle dimensions were compared using a fixed gradient, random intercept linear mixed model in 
order to account for clustering of left and right sided muscle dimensions by patient. All statistical 
analyses were done using IBM SPSS Statistics version 25 (2017). 
 
Main study  
Following from the results of the pilot study, we then extended our study to only record the VAS 
scores of all patients included. 48 patients were included (81 muscles). Recruitment and inclusion 
criteria remained the same, enlargement/ hypertrophy of the masseter was assessed and 
identified clinically and confirmed with ultrasonography. Methodology  was largely the same with 
3 main changes from the pilot study; all muscles received an intra-muscular injection of 50 
units/mL, no patient received a post-operative ultrasound scan and VAS was recorded pre-
injection and 6 weeks post-injection, as in the pilot study, but for each muscle as opposed to per 
patient. No patients were rejected from the main study after recruitment. Patients were reviewed 
at 6 months post-injection of BtA. 
 
After discussion with our local institutional research and development review board an exception 
from the requirement of ethical approval was granted for this prospective study and it was 





10 patients participated and completed the pilot service evaluation, requiring treatment to a total 
of 17 muscles.  
 
Results 1: Difference in masseteric mass pre- and post- intramuscular injection of BtA in pilot study 
All patients showed little to moderate improvement in ultrasound guided measurement of 
masseter muscle mass (Table 1). Pre-treatment clenched muscles had a mean size of 14.12mm 
(range 10-19). Post-treatment clenched muscles had a mean size of 13.29mm (range 8-18). The 
mean change in clenched muscle size was -0.82 mm (95% CI -1.96:0.315), p 0.16. Pre-treatment 
unclenched muscles had a mean size of 12.00 mm (range 8-16). Post-treatment unclenched 
muscled had a mean size of 11.00 mm (range 8-15). The mean change in unclenched muscle size 
was -1mm (95% CI -1.90:-0.098), p 0.030. 
 
Results 2: Change in VAS score pre- and post- intramuscular injection of BtA in pilot study 
Pre-treatment mean VAS score was 8.2 (95% CI 7.38-9.01). Post-treatment mean VAS score was 
1.8 (95% CI 0.85-2.74) with a mean VAS score difference of 6.4 before and after treatment (p value 
for difference < 0.01). All patients showed an improvement of reported pain before and after BtA 
injection recorded per patient (Figure 2). 
 
Main study: 
48 patients participated and completed the main service evaluation study, requiring treatment to 
a total of 81 muscles. 
 
Results 3: Change in VAS score pre- and post- intramuscular injection of BtA for each muscle in 
main study  
Pre-treatment mean VAS score was 7.94 (95% CI 7.70-8.18). Post-treatment mean VAS score was 
2.86 (95% CI 2.56-3.17) with a mean VAS score reduction of 5.08 before and after treatment (p 
value for difference < 0.05). All patients again showed an improvement in pain score before and 
after BtA injection per muscle recorded (Figure 3). 
 
Results 4: 6 month follow up main study patients 
Of 48 patients 9 (14 muscles) had moved out of area or were lost to follow up, 29 patients (49 
muscles) attended with improved symptoms and requested no further follow up and 10 patients 
(18 muscles) attended saying that the improvement they had found from the BtA injection had 





Botulinum toxin A (BtA) has been in clinical use for a number of indications for many years. It is 
effective in the management of many different clinical problems including the management of 
Frey’s syndrome (8), drooling (9), recurrent temporomandibular joint dislocation (10) and to assist 
wound healing (11). BtA is a potent neurotoxin produced by Clostridium botulinum (4).  
 
BtA’s mode of action is to block the release of acetylcholine into the synaptic cleft which suspends 
neuromuscular transmission. When injected into a muscle it reduces muscular activity (10) and in 
turn it produces muscle paralysis, weakness and atrophy (4). This should occur between days 2-20, 
but often regresses at 2 - 4 months when new terminal axons form to restore the neuromuscular 
transmission (3) and muscle paralysis starts to recover (12,13), hence why we reviewed our 
patients at 6 weeks post-injection. We routinely use it in our department for treatment of 
increased masseteric mass accompanied by pain, however in recent years due to its cost we have 
found its use increasingly scrutinised. 
 
The main concern of some patients with increased masseteric size in previously published studies 
are related to cosmetic appearance (1,4,5,6). So far Sidebottom et al are the only authors in the 
available literature to look at functional impairment, namely restriction in mouth opening (2). In 
our pilot and main studies all patients had an increase in masseteric muscle mass accompanied by 
pain and patient perceived difficulty in mouth opening.  Pain within enlarged muscles is usually 
caused when a trigger point or points develop. These contraction knots within the muscle are 
accompanied by sensitised nociceptors both with a sensory and motor element (2,14). 
 
There is an growing importance to show a measured improvement in any pathological process or 
in a patient’s pain, and hence quality of life (QoL), following a specified treatment. The importance 
of patient reported outcome measures (PROMS) has come to the forefront in the commissioning 
of healthcare services in the UK in recent years (15,16,17).  
 
The value of PROMS has become increasingly examined as part of service quality evaluation in 
research and audit. Traditional outcome measures, such as muscle mass reduction in this study, 
are now being matched by PROMS in terms of importance in service provision. For this reason it is 
now becoming more pertinent to show that a particular treatment or intervention is successful in 
both aspects (15,16).  
 
QoL, specifically health related QoL, is defined as a patient’s perception of the impact of their 
disease, or treatment of the disease, on their daily life and their physical, psychological and 
emotional wellbeing related to it (18,19). Recording a simple VAS score is a quick and easy way to 
report a patient’s overall health related QoL before and after treatment. 
  
In contrast to the clear difference in patient reported pain we were unable to show clear evidence 
for a difference in muscle dimension before and after treatment in our pilot study. Our best 
estimate is that clenched muscle dimension decreased by around 0.8 mm, and unclenched muscle 
dimensions decreased by 1.0mm, but the statistical evidence for this was equivocal (p value 0.16 
and 0.030, respectively). One potential explanation is that this service evaluation lacked statistical 
power to identify small to medium sized changes in muscle size. Alternatively, it is possible that 
there is little change in muscle mass at the low doses of BtA used in this service evaluation, which 
are lower than those reported elsewhere in the literature (3,4). Another possibility is the prospect 
that instead of hypertrophy these patients were suffering with myofascial pain and dysfunction 
from myospasm and this could be why no significant difference was seen.  
 
This service evaluation was conducted to explore patient perception and experience of treatment 
using BtA for masseteric enlargement and differs from a clinical trial.  All patients knew they were 
receiving the injection of BtA in the aim to improve their QoL by improving their pain scores, and 
this may have motivated patients to report an improved VAS score than they had actually 
experienced. There was no control group so we cannot distinguish between the effects treatment 
on pain scoring and the effect of time.   
 
VAS scoring was also not reported anonymously therefore patients may have felt pressure to 
report an improvement, or more of an improvement, than they did in fact experience. VAS scores 
were recorded on separate sheets of paper therefore the patient would not have been reminded 
of their initial score, so they could have been less tempted to simply record lower for their second 
score. 
 
VAS scores may be seen as a crude demonstration of QoL and seen as too simple. We could have 
used a longer questionnaire, for example the EQ-3D-3L, to include more specific, generic QoL 
questions to give a better picture of their perception of their overall QoL on that day. We have 
used the EQ-3D-3L previously in our department with success in the reporting of QoL after 
mandibular third molar extraction (19,20). We felt the VAS reporting gave us the information we 
required, without the need for a more-lengthy questionnaire.  
 
Similarly, the ultrasound scanning estimates of muscle dimension in the pilot study are imperfect 
and do not gain any information on the medio-lateral dimension. The exact point of reference 
within the muscle can differ at separate appointments. However, we felt this method was 
appropriate because it is non-invasive, safe and provided the information that we required in this 
study. It has also been used with success in previous studies in the area. We did not find feel it 
appropriate to perform a more validated scanning method to assess muscle dimension e.g. 
computed tomography or magnetic resonance imaging.  
 
This service evaluation provides valuable insight into the impact that masseteric hypertrophy can 
have on patients. This could lead on to further studies in to QoL related to BtA treatment of 
hypertrophy. As authors, we would recommend running full clinics of patients requiring BtA 
injection to improve productivity, and reduce wastage of BtA, particularly with single muscles 
being injected. Once the vial of BtA powder is opened and mixed with saline it must be used, or 
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Figure 1 : Visual Analogue Scale (VAS) data collection form used to report overall QoL related to 
their pain associated with masseteric hypertrophy 
 
Figure 2 : Trend in VAS difference for each patient demonstrating overall QoL change pre- and 
post- intramuscular BtA injection pilot study 
 
Figure 3 : Trend in VAS difference for each patient demonstrating overall QoL change pre- and 
post- intramuscular BtA injection main study 
 
Table 1 : Masseter muscle mass as demonstrated by ultrasonography pre- and post- intramuscular 
BtA injection pilot study 
 
